Group 1: Product Performance - The company's main products are currently in a high-efficiency and orderly production and sales state [2] - Production capacity utilization remains at a good level due to scientific capacity planning and supply chain coordination [2] - Market demand for main products is strong, with smooth sales channels and timely order fulfillment [2] - The company will continue to monitor market changes and dynamically optimize business strategies to enhance market competitiveness and share [2] Group 2: Financial Performance - In the first three quarters, the company achieved a revenue growth of 12.13% compared to the same period last year [3] - Production and operational activities are proceeding as planned and in an orderly manner [3] - The management and all employees are focused on achieving performance targets set by the equity incentive plan to deliver good results for investors [3] - Final performance results for the year will be disclosed in the company's periodic reports [3]
海森药业(001367) - 投资者关系活动记录表202501203